141 related articles for article (PubMed ID: 24886671)
21. Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
Aparicio T; Bouché O; Francois E; Retornaz F; Barbier E; Taieb J; Kirscher S; Etienne PL; Faroux R; Khemissa Akouz F; El Hajbi F; Locher C; Rinaldi Y; Lecomte T; Lavau-Denes S; Baconnier M; Oden-Gangloff A; Genet D; Bedenne L; Paillaud E;
Eur J Cancer; 2018 Jul; 97():16-24. PubMed ID: 29777975
[TBL] [Abstract][Full Text] [Related]
22. Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment.
Bennett L; Zhao Z; Barber B; Zhou X; Peeters M; Zhang J; Xu F; Wiezorek J; Douillard JY
Br J Cancer; 2011 Nov; 105(10):1495-502. PubMed ID: 21989186
[TBL] [Abstract][Full Text] [Related]
23. [A prognostic nomogram for metastasized colorectal cancer patients treated with cetuximab].
Zhong LP; Li D; Zhu LZ; Fang XF; Xiao Q; Ding KF; Yuan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jul; 23(7):701-708. PubMed ID: 32683833
[No Abstract] [Full Text] [Related]
24. Quality of life measured with EuroQol-five dimensions questionnaire predicts long-term mortality, response, and reverse remodelling in cardiac resynchronization therapy patients.
Nagy KV; Széplaki G; Perge P; Boros AM; Kosztin A; Apor A; Molnár L; Szilágyi S; Tahin T; Zima E; Kutyifa V; Gellér L; Merkely B
Europace; 2018 Sep; 20(9):1506-1512. PubMed ID: 29182734
[TBL] [Abstract][Full Text] [Related]
25. An Analysis of Relationship Between RAS Mutations and Prognosis of Primary Tumour Resection for Metastatic Colorectal Cancer Patients.
Liang L; Tian J; Yu Y; Wang Z; Peng K; Liu R; Wang Y; Xu X; Li H; Zhuang R; Cui Y; Zhu C; Liu T
Cell Physiol Biochem; 2018; 50(2):768-782. PubMed ID: 30308491
[TBL] [Abstract][Full Text] [Related]
26. Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials.
Bonnetain F; Paoletti X; Collette S; Doffoel M; Bouché O; Raoul JL; Rougier P; Masskouri F; Barbare JC; Bedenne L
Qual Life Res; 2008 Aug; 17(6):831-43. PubMed ID: 18618292
[TBL] [Abstract][Full Text] [Related]
27. Quality of life predicting long-term outcomes in cardiac resynchronization therapy patients.
Nagy KV; Merkely B; Rosero S; Geller L; Kosztin A; McNitt S; Polonsky B; Goldenberg I; Zareba W; Kutyifa V
Europace; 2019 Dec; 21(12):1865-1875. PubMed ID: 31617896
[TBL] [Abstract][Full Text] [Related]
28. Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.
Aparicio T; Gargot D; Teillet L; Maillard E; Genet D; Cretin J; Locher C; Bouché O; Breysacher G; Seitz JF; Gasmi M; Stefani L; Ramdani M; Lecomte T; Auby D; Faroux R; Bachet JB; Lepère C; Khemissa F; Sobhani I; Boulat O; Mitry E; Jouve JL;
Eur J Cancer; 2017 Mar; 74():98-108. PubMed ID: 27825697
[TBL] [Abstract][Full Text] [Related]
29. Primary tumor location as a prognostic factor in metastatic colorectal cancer.
Loupakis F; Yang D; Yau L; Feng S; Cremolini C; Zhang W; Maus MK; Antoniotti C; Langer C; Scherer SJ; Müller T; Hurwitz HI; Saltz L; Falcone A; Lenz HJ
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25713148
[TBL] [Abstract][Full Text] [Related]
30. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
31. Baseline quality of life predicts survival in patients with advanced colorectal cancer.
Maisey NR; Norman A; Watson M; Allen MJ; Hill ME; Cunningham D
Eur J Cancer; 2002 Jul; 38(10):1351-7. PubMed ID: 12091066
[TBL] [Abstract][Full Text] [Related]
32. Factors influencing quality of life (QOL) for Korean patients with rheumatoid arthritis (RA).
Cho SK; Kim D; Jun JB; Bae SC; Sung YK
Rheumatol Int; 2013 Jan; 33(1):93-102. PubMed ID: 22218643
[TBL] [Abstract][Full Text] [Related]
33. Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
Ooki A; Morita S; Iwamoto S; Hara H; Tanioka H; Satake H; Kataoka M; Kotaka M; Kagawa Y; Nakamura M; Shingai T; Ishikawa M; Miyake Y; Suto T; Hashiguchi Y; Yabuno T; Sakamoto J; Tsuji A; Ando M; Yamaguchi K
Cancer Med; 2020 Mar; 9(5):1779-1789. PubMed ID: 31962002
[TBL] [Abstract][Full Text] [Related]
34. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.
Efficace F; Innominato PF; Bjarnason G; Coens C; Humblet Y; Tumolo S; Genet D; Tampellini M; Bottomley A; Garufi C; Focan C; Giacchetti S; Lévi F;
J Clin Oncol; 2008 Apr; 26(12):2020-6. PubMed ID: 18421055
[TBL] [Abstract][Full Text] [Related]
35. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
Malka D; Boige V; Jacques N; Vimond N; Adenis A; Boucher E; Pierga JY; Conroy T; Chauffert B; François E; Guichard P; Galais MP; Cvitkovic F; Ducreux M; Farace F
Ann Oncol; 2012 Apr; 23(4):919-27. PubMed ID: 21825101
[TBL] [Abstract][Full Text] [Related]
36. Value of tumor size as a prognostic factor in metastatic colorectal cancer patients after chemotherapy: a population-based study.
Yan Q; Zhang K; Guo K; Liu S; Wasan HS; Jin H; Yuan L; Feng G; Shen F; Shen M; Ma S; Ruan S
Future Oncol; 2019 May; 15(15):1745-1758. PubMed ID: 31038364
[No Abstract] [Full Text] [Related]
37. Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.
Jary M; Lecomte T; Bouché O; Kim S; Dobi E; Queiroz L; Ghiringhelli F; Etienne H; Léger J; Godet Y; Balland J; Lakkis Z; Adotevi O; Bonnetain F; Borg C; Vernerey D
Int J Cancer; 2016 Nov; 139(10):2325-35. PubMed ID: 27472156
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial.
Giessen C; Fischer von Weikersthal L; Laubender RP; Stintzing S; Modest DP; Schalhorn A; Schulz C; Heinemann V
Br J Cancer; 2013 Sep; 109(6):1428-36. PubMed ID: 23963138
[TBL] [Abstract][Full Text] [Related]
39. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
40. The utility of abbreviated patient-reported outcomes for predicting survival in early stage colorectal cancer.
Hsu T; Speers CH; Kennecke HF; Cheung WY
Cancer; 2017 May; 123(10):1839-1847. PubMed ID: 28081292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
